NEOLEUKIN THERAPEUTICS INC (NLTX)

Company Profile

Neoleukin Therapeutics Inc is a US-based company operating in Biotechnology industry. The company is headquartered in Seattle, Washington and currently employs 7 full-time employees. The company went IPO on 2014-03-07. Neoleukin Therapeutics, Inc. is a biopharmaceutical company. The firm is engaged in providing immunotherapies for cancer, inflammation and autoimmunity using de novo protein design technology. The firm uses sophisticated computational methods to design proteins that demonstrate specific pharmaceutical properties that provide potentially superior therapeutic benefit over native proteins. Its primarily focused on cytokine mimetics, which it refers to as Neoleukin de novo cytokine mimetics. The firm operates through the research and development of de novo protein therapeutics using sophisticated computational algorithms and methods to address unmet medical needs. The firm's primary areas of focus are on oncology, inflammation, and autoimmunity. Its de novo protein design process uses a set of advanced computational algorithms and methods to design functional de novo proteins.

Company Info

NEOLEUKIN THERAPEUTICS INC

1616 Eastlake Ave E Ste 360

Seattle WASHINGTON 98102

P: 12067322133

CEO: Jonathan G. Drachman

Employees: 7

Website: https://www.neoleukin.com/